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Abstract
The treatment of schistosomiasis, a disease caused by blood flukes parasites of the Schistosoma genus, depends on the
intensive use of a single drug, praziquantel, which increases the likelihood of the development of drug-resistant parasite
strains and renders the search for new drugs a strategic priority. Currently, inhibitors of human epigenetic enzymes are
actively investigated as novel anti-cancer drugs and have the potential to be used as new anti-parasitic agents. Here, we
report that Schistosoma mansoni histone deacetylase 8 (smHDAC8), the most expressed class I HDAC isotype in this
organism, is a functional acetyl-L-lysine deacetylase that plays an important role in parasite infectivity. The crystal structure
of smHDAC8 shows that this enzyme adopts a canonical a/b HDAC fold, with specific solvent exposed loops corresponding
to insertions in the schistosome HDAC8 sequence. Importantly, structures of smHDAC8 in complex with generic HDAC
inhibitors revealed specific structural changes in the smHDAC8 active site that cannot be accommodated by human HDACs.
Using a structure-based approach, we identified several small-molecule inhibitors that build on these specificities. These
molecules exhibit an inhibitory effect on smHDAC8 but show reduced affinity for human HDACs. Crucially, we show that a
newly identified smHDAC8 inhibitor has the capacity to induce apoptosis and mortality in schistosomes. Taken together,
our biological and structural findings define the framework for the rational design of small-molecule inhibitors specifically
interfering with schistosome epigenetic mechanisms, and further support an anti-parasitic epigenome targeting strategy to
treat neglected diseases caused by eukaryotic pathogens.
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Introduction
The need for new drugs against eukaryotic parasites is acute,
notably for the neglected parasitic diseases [1] for which no
effective vaccines have yet been developed and for which the
limited number of drugs available for treatment makes increas-
ingly likely the selection of resistant parasite strains [2–5]. This is
the case for schistosomiasis (bilharzia), one of the major human
neglected parasitic diseases, which is caused by platyhelminth
parasites from the genus Schistosoma (S. mansoni, S. japonicum, S.
haematobium, S. intercalatum, S. mekongi) [6,7]. Schistosomes infect
around 200 million people worldwide and cause at least 300.000
deaths yearly, with about 800 million people further at risk of
infection [8]. The dependence of the control of schistosomiasis on
mass treatment with a single drug, praziquantel [9], and the
consequent risk of the appearance of resistant strains raises the
spectre of widespread drug resistance [10–13].
Epigenetic players are increasingly reported to be involved in
cancer genesis and progression [14–16], which explains the intense
targeting of the human epigenome to develop anti-cancer
therapies [17–22]. Interestingly, many human parasites share
several characteristics with malignant tumors, including high
metabolic activity, a dependence on lactate fermentation as an
energy source within the human host, uncontrolled (by the host)
cell division, and a degree of invisibility to the host immune
responses [23]. It is therefore expected that an approach targeting
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parasitic epigenomes would be successful in treating human
parasitic diseases caused by eukaryotic organisms.
To speed up the search for novel anti-parasitic drugs, a
‘‘piggyback’’ strategy can be used that builds on chemical scaffolds
previously validated for other diseases [24]. In humans, histone
deacetylases (HDACs) are among the most studied epigenetic
targets [25], and a variety of HDAC inhibitors affecting cancer
cells have been discovered [26–29]. HDAC inhibitors have also
been tested to fight major human parasitic diseases such as
leishmaniasis, malaria, schistosomiasis, toxoplasmosis, and try-
panosomiasis (reviewed in [2] and [23]). Yet, these studies have
highlighted the risk of cross-reactivity of the developed drugs with
host (human) enzymes that can cause off-target effects.
To tackle this bottleneck, the use of structural data, obtained
either from modeling or crystallographic/NMR studies, appears
decisive [2]. Progress using this strategy has notably been made on
Plasmodium falciparum HDAC1 (pfHDAC1), where chemical library
screening and drug design studies, based on a homology model of
this enzyme, have yielded inhibitors with anti-parasitic activity
[30–33]. Yet, the modeling approach is not sufficient to account
for all unique specificities in the active site that lead to the design
of fully specific parasite inhibitors. This problem is particularly
pronounced for many metazoan parasite epigenetic targets that,
contrary to pfHDAC1, show strong sequence conservation with
their human orthologs, notably for residues composing their active
sites, reinforcing the need for detailed structural analysis.
To address this issue, we have characterized Schistosoma mansoni
HDAC8 (smHDAC8) which has only a single active site amino
acid substitution compared with human HDAC8 (hHDAC8). We
have previously shown that S. mansoni encodes several HDACs,
and treatment with generic HDAC inhibitors caused a global
increase of protein acetylation in schistosomes and dose-dependent
mortality of schistosomula and adult worms [34–36]. Importantly,
all three S. mansoni class I HDACs (smHDAC1, 3 and 8) are
expressed at all life-cycle stages, with HDAC8 transcripts always
being the most abundant [34], indicating that this latter enzyme is
most likely a major target for the design of schistosome-specific
inhibitors. The biological role of HDAC8 has long remained
elusive. A recent study demonstrated however that human
HDAC8 (hHDAC8) is involved in deacetylation of cohesin and
mutations in hHDAC8 are linked with the Cornelia de Lange
syndrome [37].
Here, we show that smHDAC8 is essential for parasite
infectivity, reinforcing it as a potential epigenetic drug target.
Crystal structures of smHDAC8 in native form and in complex
with generic HDAC inhibitors reveal unexpected structural
features in the smHDAC8 active site. Specifically, one conserved
phenylalanine can adopt either a flipped-in or a flipped-out
conformation. Strikingly, in human HDACs, only the flipped-in
conformation is observed and appears to be fully constrained.
Structure-based chemical screening further yielded a set of small-
molecule inhibitors that, compared to generic HDAC inhibitors,
showed decreased affinity for human HDACs, while retaining
affinity towards smHDAC8. Notably, one of these inhibitors,
J1075, not only forces the phenylalanine into the flipped-out
conformation, but also induces apoptosis and mortality in
schistosomes. Our data thus confirm the validity of the
structure-based approach searching for new epigenome-targeting
drug leads against schistosomiasis, but also provides a proof of
concept for the treatment of other neglected diseases caused by
eukaryotic pathogens.
Results
Down-regulation of smHDAC8 expression in
schistosomula causes a decrease in their capacity to
survive and mature in infected mice
To investigate the importance of smHDAC8 in the schistosome
life cycle, its expression was down-regulated by RNA interference.
Transcript levels of smHDAC8 were reduced by 50% upon
exposure of in vitro transformed schistosomula after incubation
with dsRNA (‘‘soaking’’ method) in culture, whereas schistosomula
incubated with an irrelevant dsRNA encoding green fluorescent
protein (GFP) showed no reduction in smHDAC8 transcripts.
However, the microscopic examination of schistosomula treated
with smHDAC8 dsRNA in culture for up to 7 days did not reveal
any changes in tegument integrity, mortality, and motility (not
shown). We therefore decided to infect mice (by i.v. injection) with
schistosomula treated for 2 days in culture with dsRNA for
smHDAC8, GFP or untreated. The mice were subjected to whole-
body perfusion after 35 days to recover worms. Mouse livers and
intestines were also recovered in order to determine tissue egg
burdens. After 35 days post infection, mice infected with
smHDAC8 knocked-down parasites showed a significant reduc-
tion in the number of recovered adult worms (an overall 50%
reduction in comparison with the GFP dsRNA treated controls in
three independent experiments) (Figure 1A). In addition, the tissue
egg burden was reduced by 45%, again compared to the control
(GFP) (Figure 1B). We conclude from these experiments that
smHDAC8 is required for infection of the definitive host and plays
a significant role in parasite homeostasis.
smHDAC8 is a functional acetyl-L-lysine deacetylase
To characterize the role of smHDAC8, we first examined its
enzymatic activity. For this purpose, the enzyme was overex-
pressed in Escherichia coli and purified through several chromato-
graphic steps. Measurements of its deacetylase activity using a
peptide with an acetylated L-lysine as a substrate showed that
smHDAC8 exhibits a similar deacetylase activity to hHDAC8
(Figure 1C).
Author Summary
Schistosomiasis, a neglected parasitic disease caused by
flatworms of the genus Schistosoma, is responsible for
hundreds of thousands of deaths yearly. Its treatment
currently depends on a single drug, praziquantel, with
reports of drug-resistant parasites. Human epigenetic
enzymes, in particular histone deacetylases (HDACs), are
predominantly attractive inhibitory targets for anti-cancer
therapies. Validated scaffolds against these enzymes could
also be used as leads in the search for novel specific drugs
against schistosomiasis. In our study, we show that
Schistosoma mansoni histone deacetylase 8 (smHDAC8) is
a functional acetyl-L-lysine deacetylase that plays an
important role in parasite infectivity and is therefore a
relevant target for drug discovery. The determination of
the atomic structures of smHDAC8 in complex with
generic HDAC inhibitors revealed that the architecture of
the smHDAC8 active site pocket differed significantly from
its human counterparts and provided a framework for the
development of inhibitors selectively interfering with
schistosome epigenetic mechanisms. In agreement, this
information enabled us to identify several small-molecule
scaffolds that possess specific inhibitory effects on
smHDAC8 and cause mortality in schistosomes. Our results
provide the proof of concept that targeting epigenetic
enzymes is a valid approach to treat neglected diseases
caused by eukaryotic pathogens.
Structure-Based Inhibition of Schistosome HDAC8
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In human HDAC8, two residues have been shown to be critical
for activity, D101 and Y306 [38,39] (Figure 1D). The former
residue is involved in binding the backbone of the incoming
acetylated peptide substrate, whereas the hydroxyl group of the
latter participates in the catalytic mechanism. Upon mutation of
these two residues to alanine and phenylalanine, respectively, the
corresponding mutated human HDAC8 showed a strong decrease
in activity [38]. These two residues are fully conserved in
smHDAC8 (D100 and Y341) and their respective mutation into
alanine and phenylalanine also resulted in strong decrease/
complete loss of deacetylase activity (Figure 1E).
An initial homology modeling of smHDAC8 based on the hHDAC8
structure suggested that there is only a single amino acid substitution in
the catalytic pocket that distinguishes these two enzymes: the
replacement of human M274 by a histidine (smHDAC8 H292). To
investigate the importance of this substitution, we generated a
‘‘humanized’’ smHDAC8 protein by mutating H292 into methionine
(H292M). In contrast to the previous mutants, this mutation did not
affect smHDAC8 catalytic activity (Figures 1D and 1E). Mutation of
this histidine to alanine (H292A) also yielded an active enzyme
(Figure 1E), showing that this residue is not essential for activity.
Nevertheless, the presence of a charged residue replacing a hydro-
phobic one in the active site of smHDAC8 suggested a key feature that
could be exploited to design smHDAC8-specific inhibitors.
Crystal structure of smHDAC8
To gain more precise structural knowledge of smHDAC8, we
attempted crystallization of the native form of the enzyme.
Crystals were obtained that belonged to space group P1 and which
diffracted to 1.8 A˚ resolution (Table 1). The structure was solved
by molecular replacement, using human HDAC8 as a search
model. The initial model was further refined by several cycles of
manual building and automatic refinement. The final model
contains four independent non-crystallographic monomers
(r.m.s.d. on Ca’s from 0.1 to 0.6 A˚; Figure S1A), and has good
deviations from ideal geometry, with R-factor and R-free values of
0.15 and 0.19 (Table 1). Most of the residues could be built in
density, except for a few disordered loops.
The smHDAC8 adopts a fold similar to hHDAC8 [39] (r.m.s.d.
on Ca’s of 1.2 A˚ between the human and schistosome enzymes),
Figure 1. smHDAC8 is a functional acetyl-L-lysine deacetylase that is essential for parasite infectivity. (A) Down-regulation of smHDAC8
decreases the number of adult worms recovered from infected mice. (B) The number of recovered eggs from the livers of infected mice is decreased.
‘*’, p,0.05; ‘**’, p,0.01. (C) Comparison of smHDAC8 and hHDAC8 deacetylase activities. Data indicate the average of relative deacetylase activity
(hHDAC8 = 100%). Error bars represent the standard deviations (SD). (D) Close-up view of hHDAC8 active site. D101 and Y306, which participate in the
hHDAC8 catalytic mechanism, and M274, which is replaced by a histidine in smHDAC8, are displayed. (E) Deacetalyse activities of smHDAC8 wild-type
(wt), D100A, Y341F, and H292M mutants. Data indicate the average of relative deacetylase activity (smHDAC8 wt = 100%).
doi:10.1371/journal.ppat.1003645.g001
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forming a single a/b domain composed of a central, eight-
stranded parallel b-sheet sandwiched by 15 a-helices (a1–a15)
(Figures 2 and S1). The topology of the secondary structure
elements is comparable to that observed in hHDAC8 with the
exception of helix a15, which is a part of the C-terminal extension
found in smHDAC8 (Figure 2).
Interestingly, HDAC8 enzymes from different Schistosoma species
contain specific insertions compared to their mammalian orthologs
(Figure 2A). Superposition of hHDAC8 and smHDAC8 structures
reveals that these insertions extend external surface loops
(Figure 2B). These extensions are located away from the active
site, suggesting that they do not influence the catalytic mechanism
directly and may form schistosome-specific protein/protein
interaction surfaces. In addition, in human HDAC8 three ions
are bound to the enzyme: the catalytic zinc at the bottom of the
catalytic pocket, and two potassium ions. In smHDAC8 these
three ions and their coordinating residues are conserved (Figure
S1), thus reinforcing the similarity between the human and
schistosome HDAC8 enzymes.
Human HDAC8 has only been crystallized in the presence of
small-molecule inhibitors or a peptidic substrate, suggesting that
native hHDAC8 contains flexible parts, which may prevent
crystallization. We were able to crystallize smHDAC8 in a non-
inhibited form. However, we observed in our electronic density the
unambiguous presence of an L-tartrate molecule provided by the
crystallization buffer which was bound in the smHDAC8 active site
where it coordinated the catalytic zinc ion (Figures 3A, S1 and S2).
Crystals were also obtained in presence of the structurally related
succinic acid, but these crystals showed poor diffraction, probably
due to the absence of one coordinating hydroxyl group in this
molecule compared to tartrate. Collectively, these results argue for
an intrinsic flexibility of the HDAC8 active site which might be
important for substrate recognition and/or catalytic activity.
Specific architecture of the smHDAC8 catalytic pocket
Comparison of the active sites of hHDAC8 and smHDAC8
reveals several major changes between these proteins. First, as
expected, we observe the replacement of M274 by H292 in
smHDAC8 that diminishes the hydrophobic character of the
pocket that normally accommodates the aliphatic part of the
incoming acetylated lysine (Figures 3A and 3B). Further, while the
position of smHDAC8 D100 is similar to that of its human
counterpart, D101, we observe a change in conformation of the
smHDAC8 Y341 side chain compared to hHDAC8 Y306.
Specifically, the hydroxyl group of the latter is turned towards
the zinc ion, where it interacts with the warhead of the inhibitors.
In contrast, the smHDAC8 Y341 side chain points towards the
rim of the catalytic pocket (Figures 3A and 3B).
The most striking and certainly least expected difference
concerns the smHDAC8 F151 side chain that is turned away
Table 1. Data collection and refinement statistics.
Native smHDAC8 smHDAC8/SAHA smHDAC8/M344 smHDAC8/J1038 smHDAC8/J1075
Data collection
Space group P1 P1 P1 P1 P1
Cell dimensions
a, b, c (A˚) 70.7, 70.8, 98.5 70.6, 70.6, 98.0 70.6, 70.6, 98.5 70.7, 70.8, 98.5 70.3, 70.3, 98.1
a, b, c (u) 75.9, 78.3, 85.4 77.9, 75.5, 85.7 78.1, 75.4, 85.5 78.0, 75.5, 85.8 77.9, 75.6, 85.5
Resolution (A˚) 1.8 2.0 1.65 2.2 2.0
Rsym or Rmerge 0.028 (0.127)
* 0.087 (0.298) 0.058 (0.209) 0.072 (0.249) 0.124 (0.223)
I/sI 26.5 (4.9) 21.1 (3.5) 29.8 (4.8) 15.7 (3.9) 17.2 (4.6)
Completeness (%) 97.2 (93.4) 97.5 (96.5) 96.9 (95.5) 93.3 (93.1) 97.1 (95.6)
Redundancy 1.9 (1.8) 2.9 (2.8) 3.3 (3.3) 1.9 (1.8) 2.7 (2.6)
Refinement
Resolution (A˚) 31.4–1.8 34.7–2.0 24.2–1.65 32.4–2.2 20.2–2.0
No. reflections 166,214 117,868 207,374 84,066 116,580
Rwork/Rfree 0.154/0.188 0.163/0.191 0.155/0.172 0.178/0.222 0.191/0.221
No. atoms
Protein# 13,213 12,970 13,106 12,883 12,958
Ligand/ion 60 127 272 76 166
Water 1,532 926 1,171 551 632
B-factors
Protein 22.8 28.0 23.3 25.0 24.3
Ligand/ion 27.4 37.4 38.9 50.5 42.7
Water 33.3 35.1 34.8 29.9 29.7
R.m.s. deviations
Bond lengths (A˚) 0.005 0.010 0.010 0.010 0.010
Bond angles (u) 0.881 0.940 0.940 0.970 0.950
*Values in parentheses are for highest-resolution shell.
#The number of protein atoms varies slightly for each structure, depending on the quality of the electron density for poorly folded regions.
doi:10.1371/journal.ppat.1003645.t001
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Figure 2. smHDAC8 adopts a canonical HDAC fold with specific external loops. (A) Structure-based sequence alignment of schistosome,
mouse and human HDAC8 proteins. Sequences similarities are shown by levels of blue. Secondary structure elements found in smHDAC8 and
hHDAC8 are shown above and below the alignment, respectively. Residues that could not be built in densities are depicted with a black dotted line.
Important residues that participate in the specificity of the smHDAC8 active site are labeled with triangles. The numbering indicated above the
alignment corresponds to smHDAC8. For clarity, the first thirteen residues of mouse and human HDAC8 have been removed. (B) Superposition of
native smHDAC8 (green) and SAHA-inhibited hHDAC8 (blue; PDB 1T69) structures. Both enzymes adopt the same fold. smHDAC8 sequence insertions
form specific external loops and C-terminus (colored in pink). The orange sphere represents the catalytic zinc ion (Zn). (C,D) Ribbon representations of
smHDAC8 (C) and hHDAC8 (D) structures. Both enzymes adopt the same fold and their catalytic zinc ion is found at the same position.
doi:10.1371/journal.ppat.1003645.g002
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from the catalytic pocket and is inserted into a smaller
hydrophobic pocket formed by loops that surround the active site
(Figure 3A). In contrast to this flipped-out conformation of F151,
the side chain of its human counterpart, hHDAC8 F152, is turned
towards the active site adopting a flipped-in conformation in all
inhibitor- and substrate-bound hHDAC8 structures deposited in
the Protein Data Bank (PDB) (Figure 3B). Although this change
could be due to the presence of inhibitors bound to hHDAC8,
favoring a flipped-in conformation, careful inspection of hHDAC8
structures revealed that human F152 cannot adopt a flipped-out
conformation. Indeed, this conformation is incompatible with the
conformation of the L31 side chain that is itself locked in this
conformation by its surrounding neighbors (Figure 3B). In the
schistosome HDAC8 enzymes, this leucine is replaced by a serine
(S18) (Figure 2A). This smaller residue enlarges the pocket
accommodating the F151 side chain, enabling it to adopt
its observed flipped-out conformation. This conformation of
F151 appears favored over its flipped-in conformation since it
contributes to strong Van der Waals contacts in the pocket where
it is bound.
Interestingly, this phenylalanine is fully conserved in all human
HDACs. Only the first HDAC domain of human HDAC6
contains a related tyrosine at this position (Figure S3). Strikingly,
this phenylalanine is always found in a flipped-in conformation in
all human HDACs structures solved so far (Figures 3B, 3C and
3D) [39–43]. Careful investigation of hHDAC2 and hHDAC3
structures, which are also class I HDACs, showed that the flipped-
in conformation is also constrained due to the position of an
invariant tyrosine provided by a specific loop of HDAC2 and
HDAC3 (Y29 and Y18, respectively) (Figure 3C). In HDAC4 and
HDAC7, class IIa HDAC family members, a flipped-out
conformation of this phenylalanine would bring its side chain
into a strongly unfavorable close vicinity (,2.5 A˚) of the side
chains of a histidine and a glutamate residue (hHDAC7 H531 and
E543) that also affect the hydrophobic character of the pocket used
to accommodate the flipped-out conformation (Figure 3D).
Figure 3. Flipping-out of smHDAC8 phenylalanine 151 (F151) cannot be accommodated by major human HDACs. Ribbon
representation of the active sites of (A) smHDAC8, (B) hHDAC8 (PDB 1T67), (C) hHDAC3 (PDB 4A69), and (D) hHDAC7 (PDB 3COY). Residues
participating in zinc binding, catalysis, and active site formation are shown as sticks. smHDAC8 F151 and its counterparts in human HDACs are shown
as well as the residues that influence their conformation. Specifically, only the schistosome phenylalanine can adopt a favored flipped-out
conformation. Of note, the active sites of hHDAC2 (PDB 3MAX) and hHDAC4 (PDB 2VQJ) have highly similar features as observed for hHDAC3 and
hHDAC7, respectively.
doi:10.1371/journal.ppat.1003645.g003
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Therefore, the flipped-out conformation of smHDAC8 F151
appears to be highly specific to the schistosome enzyme in contrast
to human HDACs, suggesting that this feature, together with the
specific replacement of human M274 by schistosome H292, could
provide the basis for the design of specific inhibitors targeting
smHDAC8. Specifically, the flipped-out conformation of F151
prevents this residue from participating in the formation of the
narrow hydrophobic tunnel otherwise characteristic of hHDAC8
and which is required to accommodate the aliphatic part of the
acetylated lysine substrate. The consequence of this change is a
broader catalytic pocket in smHDAC8 that should be able to
accommodate bulkier inhibitors as compared to hHDAC8.
Ligand-induced gating of the catalytic pocket
Towards this goal, we first determined the structures of
smHDAC8 in complex with two generic HDAC inhibitors,
SAHA (N-hydroxy-N9-phenyloctanediamide; [44]) and M344
(N-hydroxy-7-(4-dimethylaminobenzoyl)-aminoheptanamide;
[45]), either by co-crystallization or by soaking. Crystallographic
data at 2.0 and 1.65 A˚, respectively, were collected. The refined
models have low R-factors and show good deviations from ideal
geometry (Table 1). SAHA and M344 are well-characterized
HDAC inhibitors composed of a hydroxamate metal-binding
warhead, a hydrophobic flexible linker domain, and a hydropho-
bic capping group (Figure S4 A and B). As expected, both
inhibitors coordinate the catalytic zinc ion at the active site via
their hydroxamate group. In addition, the hydroxamate head also
interacts with H141, H142 and Y341 in a fashion similar to that
observed in hHDAC8 (Figures 4 and S4). Specifically, Y341 now
adopts the same conformation as seen for Y306 in inhibited
human HDAC8 (Figure 4), a conformation that is most likely
required not only for inhibitor binding, but also for substrate
binding during catalysis as indicated by our mutation experiments
(Figure 1E).
Importantly, upon SAHA binding, smHDAC8 F151 retains its
flipped-out conformation, whereas, in human HDAC8, this
phenylalanine contributes to the hydrophobic tunnel that accom-
modates the hydrophobic linker of the SAHA molecule (Figures 4A
and 4B). The smHDAC8-bound SAHA adopts a kinked
conformation that is different from the one observed for
Figure 4. Ligand-triggered gating of the smHDAC8 active site pocket. Close-up view of the active sites of the (A) smHDAC8/SAHA, (B)
hHDAC8/SAHA (PDB 1T69), (C) smHDAC8/M344, and (D) hHDAC8/M344 (PDB 1T67) complexes shown as ribbon and sticks (upper panels), surface
view (middle panels), and side cut-away surface view (lower panels). The conformational changes of smHDAC8 Y99 and F151 compared to hHDAC8
Y100 and F152 strongly influence the binding modes of the SAHA and M344 inhibitors to these enzymes.
doi:10.1371/journal.ppat.1003645.g004
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hHDAC8-bound SAHA. This different conformation in the case
of the smHDAC8/SAHA complex is in fact enabled by the
flipped-out conformation of F151. Indeed, a flipped-in conforma-
tion of this phenylalanine would clash with the hydrophobic linker
of SAHA. This conformation further enables the hydrophobic
capping group of SAHA to stack against the Y341 side chain
(Figure 4A).
Strikingly, in the smHDAC8/M344 complex structure, we
observe that F151 is changed from its flipped-out conformation to
a flipped-in conformation, like that observed in hHDAC8
structures (Figure 4C). This flipped-in conformation of F151
contributes to M344 binding via Van der Waals contacts with the
linker domain of this inhibitor. These findings clearly demonstrate
that smHDAC8 F151 is able to adopt both flipped-out and
flipped-in conformations. Curiously, despite the fact that F151
now adopts the same conformation as human F152, the M344
inhibitor adopts a different conformation when bound to each
enzyme (Figures 4C and 4D): a straight conformation when bound
to smHDAC8, and a kinked one when bound to hHDAC8, this
latter conformation being highly similar to the one adopted by the
hHDAC8-bound SAHA (Figures 4B and 4D). This difference is
due, at least in part, to the specific conformation of smHDAC8
Y99, which is different from the conformation adopted by its
human counterpart Y100 at the rim of the active site (Figures 4C
and 4D). This change enables the capping group of smHDAC8-
bound M344 to stack onto Y99, the conformation of the inhibitor
being further stabilized through an interaction between its N10
atom and the smHDAC8 D100 carboxylate.
Structure-guided design of specific inhibitors
We next used this structural information to perform a virtual
screening to search for inhibitor scaffolds that would fit into the
enlarged catalytic pocket of smHDAC8. These attempts, based on
smHDAC8 active site specificities, aimed to identify novel
chemical scaffolds that inhibit smHDAC8 activity. The large
initial set of scaffolds identified by virtual screening was further
analyzed by biochemical and biophysical assays (see below).
Among the top-ranked inhibitors, we identified several linker-less
aromatic hydroxamate derivatives (J1037, J1038, and J1075) that
were subsequently used for structural characterization.
Soaking of these inhibitors with the native form of smHDAC8
crystals enabled the collection of crystallographic data at high
resolution for the J1038 (2-methyl-3-oxo-4H-1,4-benzothiazine-6-
carbohydroxamic acid) and J1075 (3-chlorobenzothiophene-2-
carbohydroxamic acid) inhibitors (2.2 and 2.0 A˚ resolution,
respectively; Table 1). In contrast, J1037 caused an almost
complete loss of the diffraction of the crystals. Inspection of the
structures revealed that the J1038 and J1075 inhibitors bind in the
active site of smHDAC8 and make use of the enzyme active site
specificities. Although both inhibitors coordinate the catalytic zinc
with their hydroxamate moieties in a fashion highly similar to
SAHA and M344, their modes of binding to smHDAC8 otherwise
use completely different features. Specifically, the annellated ring
systems of both inhibitors adopt perpendicular conformations
when bound to smHDAC8 (Figure 5).
Interestingly, in case of J1038, we observe that this inhibitor
forms a hydrogen bond with the side chain of smHDAC8-specific
H292, thus using one of the structural specificities of this enzyme
(Figures 5A and 5C). However, binding of J1038, like M344,
induces the F151 flipped-in conformation, this inhibitor being
therefore unable to force this phenylalanine into its schistosome-
specific conformation (Figure 5A).
In contrast, J1075 binding forces F151 to remain in its flipped-
out conformation, but does not interact with H292 (Figures 5B
and 5D). In addition, due to the presence of a bulkier chlorine
atom in J1075, this inhibitor prevents Y341 from adopting its
catalytic conformation and to coordinate the hydroxamate head
(Figures 5B and 5D). In fact, in this structure Y341 adopts an
intermediate conformation between the ones observed in the
native and inhibitor-bound forms of smHDAC8.
Thus, although J1038 and J1075 similarly bind the catalytic zinc
ion of smHDAC8 through their hydroxamate moieties, they
otherwise build their binding specificity on completely different
features. When these inhibitors, as well as J1037, were investigated
using differential scanning fluorimetry, we observed that these
molecules were able to stabilize smHDAC8 to the same extent as
SAHA and M344 (Figure S5). Importantly, these novel inhibitors
showed IC50 values for smHDAC8 in the same range as for SAHA
and M344 (Figure 6A). For human HDAC8, IC50 values were
about two-fold higher than those obtained with SAHA and M344.
Strikingly, the largest changes in IC50 values with these new
inhibitors were observed with human class I HDAC1 and HDAC3
but also class II HDAC6, with increased IC50 values up to 100 fold
(Figure 6A).
Linker-less hydroxamate derivative, J1075, causes
apoptosis and death of schistosomes
We previously showed [36] that pan-HDAC inhibitors such as
trichostatin A or valproic acid could induce the death of
schistosomula or adult worms in culture and that worm death
was due to the induction of apoptosis as evidenced by TUNEL
staining and the activation of effector caspase activities. In order to
determine whether the HDAC8-selective inhibitors J1037, J1038
and J1075 would be able to have similar effects, schistosomula
larvae were exposed to these inhibitors in culture for up to 96 h
followed by TUNEL staining to detect the induction of cell death.
These inhibitors had completely different effects: whereas J1037
and J1038 did not appear to affect the parasites up to 100 mM,
these experiments revealed TUNEL staining in schistosome cells
and parasite death upon J1075 exposure at 50 and 100 mM after
96 h (Figures 6B, 6C and 6D). In comparison, the pan-HDAC
inhibitor SAHA induces a positive TUNEL reaction within 48 h
at the same concentrations (Figure S6), as does M344. We initially
hypothesized that the faster effect observed with SAHA and M344
was due to their targeting of multiple HDACs in schistosomes.
However, we also noticed that the commercial J1075 sample we
used (supplied by Enamine, Kiev, Ukraine) contained many
impurities, and we decided to synthesize this inhibitor de novo.
Strikingly, the pure, synthesized inhibitor proved much more
effective: when incubated with schistosomula, it induced 100%
mortality at 50 mM within 3 days and was active at 10 mM
(Figure 6E). Moreover, when incubated with adult worm pairs, it
induced separation of the male and female worms, causing
complete separation of worm pairs within 3 days at 50 mM and 5
days at 20 mM (Figure 6F). Together, these results show that a
selective inhibitor of smHDAC8 has similar toxic effects on
schistosomes like pan-HDAC inhibitors, reinforcing the interest of
this enzyme as a therapeutic target and of J1075 as a lead
compound for drug development.
Discussion
The current success observed in targeting the human epigen-
ome for the development of anti-cancer drugs has broad
implications, notably concerning the discovery of novel drugs to
cure human parasitic diseases that cause millions of deaths yearly.
However, the risk of cross-reactivities of parasite-targeting drugs
with human enzymes requires careful design of inhibitors.
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Comparative structural analyses were expected to be essential for
this kind of approach. Our results demonstrate that such an
approach is valid and highly promising.
We have applied our strategy to the HDAC8 enzyme from
Schistosoma mansoni. We have shown previously that S. mansoni
HDAC8 is expressed at all life stages of schistosomes. Our current
Figure 5. Binding modes of linker-less inhibitors J1038 and J1075 to smHDAC8. Structural mechanisms of smHDAC8 inhibitions by (A)
J1038 and (B) J1075. The views are the same as those used in Figure 4. Both inhibitors make use of both common and specific interactions with
smHDAC8. J1038 induces F151 flipping-in and interacts with H292, whereas J1075 constrains F151 in its flipped-out conformation but does not
interact with H292. (C,D) Schematic views of the interactions formed by J1038 and J1075 with smHDAC8 active site zinc ion and residues.
doi:10.1371/journal.ppat.1003645.g005
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results, which indicate a marked reduction in the number of
recovered adult worms after infection of mice with schistosomula
knocked-down for smHDAC8, confirm the importance of this
protein as a therapeutic target. However, sequence alignment
showed almost complete conservation of active site residues
between schistosome and human HDAC8.
By comparing the structure of S. mansoni HDAC8 in native and
inhibited forms with the structures of inhibited human HDAC8,
we observe, despite this high sequence conservation of active site
residues, different changes in the active site that increase the
possibility of designing specific inhibitors. Notably, two substitu-
tions, M274RH292 and L31RS18, directly and indirectly modify
Figure 6. Designed small-molecule inhibitors show decreased specificity towards human HDACs and induce apoptosis in
schistosomes. (A) IC50 values of SAHA, M344, J1038, J1037, and J1075 for smHDAC8 and human HDAC8, HDAC1, HDAC3, HDAC6 are plotted in
graph. J1038 and J1075 show loss of specificities for human HDACs but not for smHDAC8. The results of three independent assays are shown, error
bars represent the SD. (B,C) Merged TUNEL (pink) and DAPI (blue) staining of S. mansoni schistosomula incubated with DMSO alone (B) or with
100 mM J1075 dissolved in DMSO (C) for 96 h. (D) Quantification of TUNEL positivity of schistosomula incubated for 96 h with J1075 at 50 mM or
100 mM or with DMSO alone. The results of three independent assays are shown, error bars represent the SD. (E) Dose- and time-dependent mortality
of schistosomula induced by J1075 inhibitor. Schistosoma mansoni schistosomula (1000 per well) were incubated in 1 mL of culture medium with
varying quantities of J1075 inhibitor or the solvent (DMSO). The results of three independent assays are shown; error bars represent the SD. (F) J1075-
triggered separation of S. mansoni adult worm pairs in culture. The paired status of male and female adult worms was assessed daily in the presence
of varying quantities of J1075 or the solvent (DMSO). The results of three independent assays are shown, error bars represent the SD.
doi:10.1371/journal.ppat.1003645.g006
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the shape and physico-chemical properties of the smHDAC8
active site (Figures 3 and 4).
The consequence of the S18 substitution concerns F151 that
adopts a flipped-out conformation that cannot be accommodated
in human HDAC8 and other major human HDACs. The reason
for this preferred flipped-out conformation is unclear. It has been
suggested that human HDAC8 [39] contains an exit channel for
the cleaved acetate molecule that starts at the bottom of the
catalytic cavity and goes through the enzyme, a feature also
observed in bacterial histone deacetylase-like proteins (HDLPs)
[46,47]. Surprisingly, this internal channel is absent in smHDAC8
because of several substitutions introducing residues with bulkier
side chains (Figure 7). Therefore, the flipping-out of F151 could
provide an alternative to the exit channel and facilitate exit of the
acetate product. We cannot exclude, alternatively, that the F151
flipping-out enables the recognition of a structurally different
substrate. Such plasticity could be used to adapt to various
epigenetic regulations that drive the intricate parasitic life cycle
that presents several phenotypically very different stages.
An important result from our study is that the novel linker-less
inhibitors designed according to our initial structures are able to
make use of the smHDAC8 active site pocket specificities,
retaining an inhibitory effect on smHDAC8, but showing
significant loss in potency for major human HDACs such as
HDAC1, HDAC3, and HDAC6 as off-targets. Although IC50
values also increased for human HDAC8, this phenomenon was
less pronounced than for the other human HDACs tested. Our
structural data suggest that HDAC8 enzymes display some
flexibility at their active sites, which could explain that small
molecules (e.g. L-tartrate in our native form and inhibitors in the
other cases) coordinating the catalytic zinc are required to stabilize
the protein and support crystallization. This intrinsic flexibility
could contribute to the better accommodation of our linker-less
inhibitors by hHDAC8 than other human HDACs. However, our
structures of smHDAC8 bound to these novel inhibitors reveal
that this enzyme could accommodate even bulkier linker-less
inhibitors. Our current inhibitors therefore form the building
blocks for the design of second generation inhibitors that should
show increased specificity towards smHDAC8 versus hHDAC8.
Of note, whereas the increase of IC50 values observed with
J1075 for human HDACs is certainly due to the inability of these
HDACs to have a phenylalanine in the flipped-out conformation,
the reason for this increase with J1038, and possibly for the related
J1037 inhibitor, is most likely different. In smHDAC8 we have
seen that H292, which interacts with J1038 through a hydrogen
bond, is replaced by a methionine in hHDAC8, which is certainly
not favorable for J1038 binding. In human HDAC2 and HDAC3
(but also in human HDAC4 and HDAC7), a leucine residue,
protruding deeper into the active site pocket, is found at the
position of M274 that should cause even stronger hindrance for
the optimal binding of J1038, as suggested by our inhibition
experiments. Since HDAC6 also shows increased IC50 values, it is
likely that a similar mechanism is at play with this enzyme.
However, the fact that HDAC6 structure is unknown and that this
protein is composed of two HDAC domains arranged in tandem
currently impairs its accurate modeling and prevents an interpre-
tation of our results in molecular terms.
Our complementary in vivo studies support our structural and
biochemical results, J1075 being able to induce apoptosis and
death of schistosomes, as well as the unpairing of adult worms.
Since the maintenance of adult worm pairs is necessary for egg-
laying, which in turn is responsible for the pathological effects of
schistosome infection, worm unpairing may indicate that the
inhibition of smHDAC8 will lead to reduced morbidity. The
reason for the apparent inefficiency of J1037 and J1038 in both
assays remains unclear. Poor uptake or metabolic inactivation may
be possible explanations for these observations. The design of
more specific inhibitors based on our current structural data
should help to reduce the possible residual toxicity in human cells
and increase the capacity to kill schistosomes.
Most HDAC inhibitors that are currently approved for use in
humans, or are in clinical trials are, at best, moderately selective
for an HDAC class [48] and not for one particular enzyme. Our
objective is to maximize the selectivity of the inhibitors we develop
in order to avoid possible side-effects that can be associated with
treatment with HDAC inhibitors. For instance, side-effects of
treatment with Vorinostat (SAHA) include fatigue, nausea and
diarrhea, but the most severe adverse effect observed with HDAC
inhibitors has been cardiac toxicity, including ventricular arrhyth-
mia (see [49] for review). However, the dosing schedule for HDAC
inhibitors in cancer therapy usually involves multiple doses given
over a long period. The objective for the treatment of schistoso-
miasis is to develop a single dose strategy, as is the case for
praziquantel. Together with selectivity for the schistosome enzyme
Figure 7. smHDAC8 lacks a putative acetate exit channel. The cut-away surface views of (A) smHDAC8, (B) hHDAC8, and (C) bacterial HDAC-
like HDLP. These snapshots reveal the absence of typical, continuous internal cavity connecting the active site with the outside environment in
smHDAC8. Careful inspection of the smHDAC8 structure did not reveal an obvious alternative channel at another location. The catalytic zinc ion at
the active site is depicted by an orange sphere.
doi:10.1371/journal.ppat.1003645.g007
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over human HDACs, this should ensure that the side effects of
treatment are minimal.
So far, our study has been dedicated to the inhibition of S.
mansoni HDAC8. However, this study is expected to have broader
implications. Notably, smHDAC8 S18, which enables F151
flipping out, is conserved in all schistosome HDAC8 enzymes
sequenced so far, including S. japonicum and S. haematobium
(Figure 2A), as well as another trematode species, Clonorchis sinensis
(Figure S7). The same is true for smHDAC8 H292. Homology
modeling of the HDAC8 structures from these different species
based on sequence alignment and our structural data did not
suggest any amino acid substitution in these enzymes that could
prevent, directly or indirectly, F151 to adopt its flipped-out
conformation. These observations are of paramount importance
since they imply that smHDAC8-specific inhibitors should also
inhibit the corresponding enzymes of S. japonicum, S. haematobium
and C. sinensis, and possibly those of other trematode species that
affect different populations worldwide. Moreover, S. haematobium
and C. sinensis are also linked with the progression of cancer
(reviewed in [50]). Hence, development of drugs fighting these
infections should also have an implication in cancer prevention.
Strikingly, smHDAC8 S18 but also smHDAC8 H292 are
conserved in the recently published HDAC8 sequences of the
cestodes Echinococcus multilocularis, Echinococcus granulosus and Taenia
solium [51] that also cause serious human diseases (Figure S7).
Modeling of the structures of HDAC8 from E. multilocularis, E.
granulosus and T. solium reveals that the active sites of these enzymes
are highly conserved compared to that of smHDAC8. Specifically,
as for the various schistosome species, the flipped out conforma-
tion of the phenylalanine corresponding to smHDAC8 F151
should also be conserved in these enzymes. In addition, the
position of the histidine corresponding to smHDAC8 H292 should
be the same as in the schistosome enzyme. These results suggest
that the specific drugs developed against smHDAC8 could in fact
be used in a pan-platyhelminth treatment strategy.
Taken together, our results provide the molecular basis
for specific targeting a parasitic epigenetic enzyme to cure
parasitic diseases by combining high resolution structural data
with biochemical and in vivo studies. These results pave the way for
similar studies on various platyhelminth epigenetic players,
but also on other major parasites that, among others, cause
malaria, leishmaniasis, Chagas disease, toxoplasmosis, and
trypanosomiasis.
Materials and Methods
Ethics statement
Experiments involving mice were carried out according to the
European directive 2010/63/EU concerning the use of animals
for scientific purposes. Specifically, Brazilian national guidelines
set out in the Law 11794/2008 were followed, stipulating the
conditions for the use of animals in scientific research and setting
up the National Council for the Control of Animal Experimen-
tation (CONCEA) requiring the establishment of ethics commit-
tees on the use of animals (CEUA) by institutions under
operational standards set out in Decree 6899/2009,2. According-
ly, animal experiments carried out in this work were approved by
the Ethics Review Committee for Animal Experimentation
(CETEA) of Universidade Federal de Minas Gerais number
185/2006.
RNAi-mediated knockdown of smHDAC8
The smHDAC8 specific PCR primers containing the T7
promoter-tail amplified a ,500 bp fragment (dsRNA-smHDAC8
Forward 59-TAATACGACTCACTATAGGGGATACGCCTT-
GGTCAT GGAT-39, and dsRNA-smHDAC8 Reverse 59-TAA-
TACGACTCACTATAGGGTGTACCG GGAAAGAAACCA-
G-39). A GFP nonspecific ,500 bp control was used (dsRNA-
GFP Forward 59-TAATACGACTCACTATAGGGTCTTCA-
AGTCCGCCATG-39 and dsRNA-GFP Reverse 59-TAATAC-
GACTCACTATAGGGTGCTCAGGTAGTGGTTGTC-39).
Double-stranded RNAs (dsRNAs) were synthesized in vitro from
schistosomula cDNA using T7 RiboMAX Express RNAi Kit
(Promega). Schistosomula were obtained by mechanical transfor-
mation of cercariae [52] of the LE strain of S. mansoni and cultured
in supplemented MEM medium. Schistosomula (2000 per assay
point) were exposed to 100 mM of dsRNA and cultured for 2 days
at 37uC under CO2. For qRT-PCR (minimum of 3 experiments)
total RNA was extracted using the RNeasy Mini Kit (Qiagen).
Total RNA (100 ng) was used to synthesize cDNA with
Superscript III cDNA Synthesis kit (Life Technologies). S. mansoni
cytochrome oxidase was used as an endogenous normalization
control in all tested samples (GenBank AF216698) (COX Forward
59-TACGGTTGGTGGTGTCACAG-39 and COX Reverse 59-
ACGGCCATCACCATACTAGC-39). Quantitative RT-PCR
was carried out using Power SybrGreen PCR Master Mix (Life
Technologies) in an AB7900 Real Time PCR System (Life
Technologies). Negative controls used were GFP and two internal
controls assessing both possible genomic DNA contaminations (no
reverse transcriptase) and purity of the reagents (no cDNA). Each
experiment was repeated 3–5 times and analyzed using the DDCt
method [53].
In vivo experiments – Recovery of adult worms and eggs
SWISS Webster mice were infected with 300 schistosomula
treated with dsRNA for 2 days (3 independent experiments, 5 or 6
animals per group). After 35 days parasites were perfused
according to standard protocols [54]. Livers from infected animals
were weighed and eggs counted after digestion with KOH.
Cloning, protein expression and purification
The full-length cDNA for smHDAC8 [34] was PCR-amplified
using the forward primer smHDAC8-N (59-GGATATCC-
ATATGTCTGTTGGGATCGTTTATG-39) and the reverse
primer smHDC8-CNS (59-CGCGGATCCCATACCAGTTAA-
ATTATATAATTG-39). The amplified gene was cloned between
the NdeI and BamHI sites of the pnEA/tH vector encoding a C-
terminal thrombin cleavage site followed by a His-tag [55]. The
mutants were generated using standard nested protocols and
inserted into the same vector.
Overexpression was carried out in E. coliBL21(DE3) cells in
Terrific Broth (TB) medium. Induction was done at 37uC by
adding 0.5 mM final isopropyl-1-thio-b-D-galactopyranoside
(IPTG, Euromedex), in presence of 100 mM ZnCl2. Harvested
bacteria were resuspended in lysis buffer (50 mM KCl, 10 mM
Tris-HCl pH 8.0) and lysed under high pressure (18000 psi) in a
Microfluidizer Processor M-110EH (Microfluidics). The lysate was
clarified by ultracentrifugation (40000 rpm, Ti45 Beckman) for
1 h. The supernatant was loaded onto Talon Metal affinity resin
(Clontech) pre-equilibrated with the lysis buffer. The His-tagged
smHDAC8 protein was released from the Talon resin by thrombin
treatment and subsequently loaded onto a 1-mL HiTrap Q FF
(GE Healthcare) column pre-equilibrated with the lysis buffer. The
protein was eluted by a linear gradient of KCl (50 mM to 1 M
KCl) and then loaded onto HiLoad 16/60 Superdex 200 gel
filtration column (Amersham Bioscience) equilibrated in 50 mM
KCl, 10 mM Tris-HCl pH 8.0, and 2 mM DTT. The protein was
concentrated with an Amicon Ultra centrifugal filter units
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(Millipore) to reach a final concentration of 2 mg/ml as assayed by
the Bio-Rad Protein Assay reagent (Bio-Rad).
Crystallization and data collection
Crystallization trials were performed using both sitting and
hanging drop vapor diffusion techniques. Diffraction-quality
crystals were obtained at 17uC after three to four days by mixing
equal volumes of smHDAC8 with reservoir solution composed of
21% PEG 3350 (Fluka) and 0.2 M Na+/K+ L-tartrate. The
smHDAC8/SAHA complex was formed by incubating the
smHDAC8 protein (2 mg/ml) with SAHA (5 mM resuspended
in DMSO) at 4uC for 1 h. Crystals were grown in the same
conditions as described for native smHDAC8.
Crystals of the complexes of smHDAC8 with the inhibitors
M344, J1038 and J1075 inhibitors were produced by soaking
native smHDAC8 crystals in mother liquor supplemented with the
corresponding inhibitor (10 mM resuspended in DMF) for
20 hours. Crystals used for X-ray data collection were briefly
transferred in reservoir solution supplemented with 20% glycerol
and flash-frozen in liquid nitrogen. All data obtained in this project
were collected at 100 K on ESRF beamline ID23-1 and SOLEIL
beamline PROXIMA1.
Structure determination, model building and refinement
All data were processed and scaled using HKL2000 [56]. The
structure of native smHDAC8 at 1.8 A˚ resolution was solved by
molecular replacement with Phenix [57] using the hHDAC8
structure (PDB 1T69) as a search model. The crystals of the
smHDAC8/SAHA, smHDAC8/M344, smHDAC8/J1038, and
smHDAC8/J1075 complexes all belonged to the same space
group and had the same unit cell as native SmHDAC8 crystals,
and only rigid-body refinement was used to adapt to the slight
differences in unit cell constants.
The initial models were refined through several cycles of
manual building using COOT [58,59] and automated refinement
with Phenix [57] and Buster [60]. All models have low R and R-
free factors, good deviations from ideal geometry (Table 1), and no
Ramachandran outliers. Crystal structures solved in this project
have been deposited under the codes 4bz5, 4bz6, 4bz7, 4bz8 and
4bz9 in the Protein Data Bank. Alignments were generated with
JalView [61], structural panels in figures were generated with
PyMOL (DeLano Scientific), and schematic interactions of the
inhibitors with smHDAC8 were generated with LigPlot [62]).
Virtual screening
Virtual screening was carried out using the native smHDAC8
structure as template. We screened the Enamine purchasable
compound library (1.587.660 compounds) for potential smHDAC8
inhibitors by a stepwise virtual screening procedure. First we
screened for compounds containing hydroxamic acid groups or
derivatives which are known as zinc binding motifs. The molecular
weight was restricted to 300 Daltons to identify smaller lead-like
compounds. In total 25 molecules were retrieved, their 3D structures
were generated within MOE 2008.10 (Chemical Computing Group,
Montreal, Canada) and docked into the smHDAC8 structure using
GOLD4.1 docking program [63]. ChemScore was used as scoring
function due to the success of ChemScore in earlier HDAC dockings
[64]. The docking region was defined within a radius of 15 A˚ around
the zinc ion. The docking showed that the top-ranked hydroxamates
are well coordinated to the zinc ion. The top-ranked compounds
(J1037, Enamine compound ID Z285139392; J1038, Enamine
compound ID Z253047366; J1075, Enamine compound ID
Z1269129447) were further considered for inhibition assays in vitro
and for structural work.
J1075 synthesis
The hydroxamic acid (J1075) was synthesized through a fast two-
step synthesis, starting from cinnamic acid which is transformed into
3-chlorobenzo[b]thiophene-2-carbonyl chloride by a ring closure
using thionyl chloride as solvent/reagent, and pyridine as a catalyst
(by a modification of the procedure described [65]. The carbonyl
chloride was further reacted into the hydroxamic acid 3-chloro-N-
hydroxybenzo[b]thiophene-2-carboxamide (J1075) using a proce-
dure similar to one already described in [66].
Activity and inhibition assays
Human and smHDAC8 activity testing was carried out with the
HDAC8 Fluorimetric Drug Discovery Kit (Fluor de Lys(R)-
HDAC8, BML-KI178) from Enzo Life Sciences according to the
manufacturer’s instructions with a substrate concentration of
50 mM. Fluorescence was measured in a plate reader (BMG
Polarstar) with excitation at l= 390 nm and emission at
l= 460 nm. Inhibition data for human HDACs 1, 3 and 6 were
obtained according to published procedures with Z(Ac)Lys-AMC
as the substrate and trypsin as the developing agent [67]. HDAC1,
3 and 6 were purchased from BPS Bioscience.
Differential scanning fluorimetry assays
The full-length smHDAC8 protein was added to a final
concentration of 0.25 mg/ml in the incubation buffer (50 mM
KCl, 10 mM Tris-HCl pH 8.0, and 56 SYPRO Orange
(Invitrogen) fluorescent dye). The final volume was 30 ml/well in
a PCR plate. The temperature gradient was performed in the
range of 20–95uC with a heating rate of 0.5uC/min, using a
MiniOpticon real-time detection system (Bio-Rad) with excitation
at 490 nm and emission at 530 nm. The midpoint temperature
values of the unfolding transition (Tm) were generated with help of
Opticon Monitor 3 (Bio-Rad) program. The DTm of the
smHDAC8 protein for a specific inhibitor was calculated as the
difference between the Tm values of the inhibitor-bound and
inhibitor-free proteins. All the assays were done in triplicate.
Treatment of schistosomula with HDAC inhibitors in culture
A Puerto-Rican strain of S. mansoni was maintained in Biomphalaria
glabrata snails and golden hamsters (Mesocricetus auratus). Cercariae
released from infected snails were harvested on ice, washed 3 times
by resuspension in 30 ml of Hank’s Balanced Salt Solution
(Invitrogen) in a corex tube (Corning) and centrifugation for
10 min. at 1500 g. Schistosomula were obtained in vitro [52] and
were maintained in culture for up to 8 days under the conditions
previously described [36]. Detection of DNA strand breaks in TSA-
treated schistosomula was done using the dUTP nick end labelling
(TUNEL) method using the In Situ Cell Death Detection Kit TMR
Red (Roche). The method designed for cell suspensions was followed
as described in the manufacturer’s instructions with the modifica-
tions described previously [36]. Positively labelled schistosomula
were counted manually under fluorescence microscopy. Alterna-
tively, the viability of schistosomula was visually estimated on a daily
basis using an optical microscope (Leica DMIL) following the
distinct morphological differences between dead and viable schis-
tosomula. Loss of mobility, obvious tegumental deformation and a
granular appearance were the main criteria. For each condition, an
aliquot of approximately 150 larvae was observed and the non-
viable larvae were counted. Three counts were independently
performed for each experiment. Adult worm pairing was assessed
visually for 8 worm pairs maintained in culture under the same
conditions as for schistosomula. For the viability and pairing assays
three independent experiments were carried out in duplicate.
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Supporting Information
Figure S1 Structural features of smHDAC8. (A) Four non-
crystallographic smHDAC8 monomers (A to D) are observed in
the asymmetric unit. Root-mean-square deviation (r.m.s.d.)
between each monomer range from 0.1 to 0.6 A˚. (B) Ribbon
representations of the smHDAC8 structure. The L-tartrate
molecule bound in the active site is drawn with sticks. Orange
sphere, catalytic zinc ion; blue spheres, potassium ions. (C) Close-
up view of both the smHDAC8 active site and potassium-binding
site A (KA site). Residues involved in zinc and KA binding are
drawn in stick representation. The carbon atoms of proteins side
chains are in grey, whereas the carbon atoms of L-tartrate are in
yellow. The associated multiple alignment shows the conservation
of the residues coordinating the zinc ion (orange circles) and the
KA ion (blue circles) among HDAC8 family members as well as
the HDAC-like bacterial protein HDLP. Note that the tartrate
molecule also coordinates the zinc. (D) Close-up view of the
potassium binding site B (KB site). Residues involved in the KB ion
coordination are drawn in sticks. The red sphere represents a
water molecule. The associated alignment shows conservation of
residues coordinating the KB ion (blue squares).
(TIF)
Figure S2 Interaction between native smHDAC8 and the L-
tartrate molecule. (A) Chemical structure of L-tartrate molecule. (B)
Schematic view of the interactions made by the tartrate molecule as
well as the smHDAC8 catalytic zinc ion. The hydrogen bonds and
salt bridges observed in the crystal structure are shown with green
dotted lines together with their associated distances (A˚). Black
circles, carbon atoms; red circles, oxygen atoms; blue circles,
nitrogen atoms; orange circle, zinc atom. Proteins side chains are in
grey, while the L-tartrate scaffold is in yellow.
(TIF)
Figure S3 Sequence alignment of smHDAC8 and all human
HDACs in the vicinity of the phenylalanine (indicated by a
triangle) which adopts either a flipped-in or a flipped-out
conformation. Note that hHDAC6 contains two deacetylase
domains, which are here designed as hHDAC6-I and hHDAC6-
II. The phenylalanine is conserved in all human HDACs, except
in the first HDAC domain of hHDAC6 where it is replaced by a
tyrosine. Sequence conservation is indicated with blue levels.
(TIF)
Figure S4 Molecular interactions between smHDAC8 and the
generic hydroxamate inhibitors SAHA and M344. (A,B) Chemical
structures of SAHA and M344. (C,D) Schematic view of the
interactions made by the SAHA and M344 inhibitors with
smHDAC8. The same color codes are used than in Figure S2.
(TIF)
Figure S5 Thermal stabilization of smHDAC8 in presence of
the SAHA, M344, J1038, J1037, and J1075 inhibitors. The values
represent the mean difference of melting temperatures (DTm)
observed for smHDAC8 in presence and absence of inhibitors
plotted and calculated from three independent assays. Error bars
represent the standard deviation (SD).
(TIF)
Figure S6 Quantification of TUNEL positivity of schistosomula
incubated for 48 h with 0, 20, 50 or 100 mM of SAHA dissolved in
DMSO. Results are expressed as the mean values of two
independent experiments, with error bars giving the SD.
(TIF)
Figure S7 Sequence alignment of schistosome, Echinococcus
multilocularis, Echinococcus granulosus, Taenia solium, Clonorchis sinensis
and human HDAC8 proteins. Sequences similarities are shown by
levels of blue. Important residues that participate in the specificity
of Schistosoma mansoni HDAC8 active site and are conserved in the
other platyhelminthes HDAC8 proteins are labeled with triangles.
The numbering indicated above the alignment corresponds to
smHDAC8.
(TIF)
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